- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ascendis Pharma AS (ASND)
Ascendis Pharma AS stock price live, this page displays NASDAQ ASND stock exchange data. View the ASND premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ascendis Pharma AS real time stock price chart below.
What Is the Ascendis Pharma AS Stock Price Today?
The Ascendis Pharma AS stock price today is 222.15.
What Is the Stock Symbol for Ascendis Pharma AS?
The stock symbol for Ascendis Pharma AS is "ASND."
What Stock Exchange Does Ascendis Pharma AS Trade On?
Ascendis Pharma AS is listed and trades on the NASDAQ stock exchange.
Is Ascendis Pharma AS a Good Stock to Buy?
Determining whether Ascendis Pharma AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ASND quote. (ISIN: US04351P1012)
What Is the Ascendis Pharma AS Stock Price Today?
The Ascendis Pharma AS stock price today is 222.15.
What Is the Stock Symbol for Ascendis Pharma AS?
The stock symbol for Ascendis Pharma AS is "ASND."
What Stock Exchange Does Ascendis Pharma AS Trade On?
Ascendis Pharma AS is listed and trades on the NASDAQ stock exchange.
Is Ascendis Pharma AS a Good Stock to Buy?
Determining whether Ascendis Pharma AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ASND quote. (ISIN: US04351P1012)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
212.70
223.24
52 wk Range
118.03
242.00
Earnings results expected in 4 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
212.70223.24
52 wk Range
118.03242.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ASND Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
276.14
Upside
+24.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- Ascendis Pharma shares hit new high
- Investing.com
- Ascendis Pharma shares hit new high
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Ascendis Pharma AS Company Profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ascendis Pharma AS SWOT Analysis
Pipeline Promise | Ascendis Pharma's innovative therapies for rare endocrine disorders show potential, with Yorvipath exceeding expectations and a promising achondroplasia treatment in development. |
Market Dominance | Explore Ascendis' first-mover advantage in hypoparathyroidism treatment, with Yorvipath projected to become a multi-billion euro drug in a market of 90,000 U.S. patients. |
Financial Trajectory | Delve into Ascendis' projected revenue growth from €363.6 million in 2024 to €1.72 billion by 2027, with analysts expecting profitability by 2026. |
Analyst Optimism | Learn about Wall Street's bullish stance on Ascendis, with price targets ranging from $170 to $250 and a highly favorable consensus rating of 1.25. |
Ascendis Pharma AS Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -0.82 beat forecast of -1.27; revenue of €158M surpassed €142.38M estimate
- Yorvipath revenue doubled from Q1 to €103M; company plans cash flow positivity by 2025
- Stock rose 4.87% after-hours to $191.49; market cap at $12.01B with strong buy consensus
- Phase 3 trial for achondroplasia combo therapy planned; PDUFA date for TransCon CNP set for Nov 30, 2025
- CEO expects 'billions of euros annually in peak sales' for Yorvipath; R&D costs decreased to €72M
Last Updated: 2025-08-20, 09:24 p/m
Read Full TranscriptCompare ASND to Peers and Sector
Metrics to compare | ASND | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASNDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −49.5x | −1.3x | −0.5x | |
PEG Ratio | −1.03 | −0.02 | 0.00 | |
Price/Book | −66.3x | 1.1x | 2.6x | |
Price / LTM Sales | 17.8x | 32.8x | 3.3x | |
Upside (Analyst Target) | 16.4% | 85.7% | 45.7% | |
Fair Value Upside | Unlock | 22.3% | 6.5% | Unlock |
Analyst Ratings
16 Buy
0 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 276.14
(+24.30% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
-1.00 / -0.28
Revenue / Forecast
213.63M / 213.17M
People Also Watch
FAQ
What Is the Ascendis Pharma AS (ASND) Stock Price Today?
The Ascendis Pharma AS stock price today is 222.15
What Stock Exchange Does Ascendis Pharma AS Trade On?
Ascendis Pharma AS is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Ascendis Pharma AS?
The stock symbol for Ascendis Pharma AS is "ASND."
What Is the Ascendis Pharma AS Market Cap?
As of today, Ascendis Pharma AS market cap is 13.64B.
What Is Ascendis Pharma AS's Earnings Per Share (TTM)?
The Ascendis Pharma AS EPS (TTM) is -3.87.
When Is the Next Ascendis Pharma AS Earnings Date?
Ascendis Pharma AS will release its next earnings report on Feb 11, 2026.
From a Technical Analysis Perspective, Is ASND a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Ascendis Pharma AS Stock Split?
Ascendis Pharma AS has split 0 times.
How Many Employees Does Ascendis Pharma AS Have?
Ascendis Pharma AS has 1017 employees.
What is the current trading status of Ascendis Pharma AS (ASND)?
As of Feb 07, 2026, Ascendis Pharma AS (ASND) is trading at a price of 222.15, with a previous close of 217.38. The stock has fluctuated within a day range of 212.70 to 223.24, while its 52-week range spans from 118.03 to 242.00.
What Is Ascendis Pharma AS (ASND) Price Target According to Analysts?
The average 12-month price target for Ascendis Pharma AS is USD276.14, with a high estimate of USD337.59541534 and a low estimate of USD244.48068061. 16 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +24.30% Upside potential.
What Is the ASND Premarket Price?
ASND's last pre-market stock price is 217.90. The pre-market share volume is 10.00, and the stock has decreased by 0.52, or 0.24%.
What Is the ASND After Hours Price?
ASND's last after hours stock price is 224.00, the stock has decreased by 1.85, or 0.83%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.